Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.55 |
| ▸ | MAPT | P10636 | 12/20 | 0.55 |
| ▸ | MEN1 | O00255 | 12/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 8/20 | 0.55 |
| ▸ | HPGD | P15428 | 7/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | CUL4A | Q13619 | 5/20 | 0.54 |
| ▸ | CASP1 | P29466 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | CASP7 | P55210 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7820645 | 0.75 | KDM4E (0.54) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL13295969 | 0.73 | ALDH1A1 (0.49) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL15572548 | 0.71 | CUL4A (1.00) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL3324580 | 0.69 | ALDH1A1 (0.45) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL15572039 | 0.67 | CUL4A (1.00) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL15572213 | 0.66 | EEF2K (1.00) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL15571632 | 0.63 | MEN1 (0.68) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL7275798 | 0.63 | KDM4E (0.58) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL31567856 | 0.63 | MEN1 (1.00) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL187001 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104968323-B | CRL4 ubiquitin ligase inhibitors and uses thereof | 康奈尔大学 | 2020-08-21 | — | — | CN | claimed |
| US-10617683-B2 | Inhibitors of CRL4 ubiquitin ligase and uses thereof | CORNELL UNIVERSITY (US) | 2020-04-14 | — | — | US | claimed |
| US-20150196546-A1 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY | 2015-07-16 | — | — | US | claimed |
| EP-2887940-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | Cornell University (US) | 2015-07-01 | — | — | EP | claimed |
| WO-2014031759-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-02-27 | — | — | WO | claimed |
| CN-104968323-B | CRL4 ubiquitin ligase inhibitors and uses thereof | 康奈尔大学 | 2020-08-21 | — | — | CN | disclosed |
| US-10617683-B2 | Inhibitors of CRL4 ubiquitin ligase and uses thereof | CORNELL UNIVERSITY (US) | 2020-04-14 | — | — | US | disclosed |
| EP-2887940-B1 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | UNIV CORNELL (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20150196546-A1 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| EP-2887940-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | Cornell University (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031759-A2 | INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | KMT2A 2463/4885ALDH1A1 534/4885MAPT 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.